vs
Side-by-side financial comparison of Amneal Pharmaceuticals, Inc. (AMRX) and Gen Digital (GEN). Click either name above to swap in a different company.
Gen Digital is the larger business by last-quarter revenue ($1.2B vs $722.5M, roughly 1.7× Amneal Pharmaceuticals, Inc.). Gen Digital runs the higher net margin — 15.5% vs 10.8%, a 4.7% gap on every dollar of revenue. On growth, Gen Digital posted the faster year-over-year revenue change (28.5% vs 3.9%). Over the past eight quarters, Gen Digital's revenue compounded faster (13.2% CAGR vs 1.5%).
Amneal Pharmaceuticals, Inc. is an American publicly traded pharmaceutical company that develops, manufactures and distributes generics and specialty pharmaceutical products. The company is headquartered in Bridgewater, New Jersey, and is one of the largest manufacturers of generic drugs in the United States.
Gen Digital Inc. is a multinational software company co-headquartered in both Tempe, Arizona (USA) and Prague, Czech Republic (EU). The company provides cybersecurity software, financial technology, and services. Gen is a Fortune 500 company and a member of the S&P 500 stock-market index. It is listed at both NASDAQ and Prague Stock Exchange. Its portfolio includes Norton, Avast, LifeLock, Avira, AVG, ReputationDefender, MoneyLion and CCleaner.
AMRX vs GEN — Head-to-Head
Income Statement — Q1 FY2026 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $722.5M | $1.2B |
| Net Profit | $78.0M | $192.0M |
| Gross Margin | 44.3% | 78.4% |
| Operating Margin | — | 34.9% |
| Net Margin | 10.8% | 15.5% |
| Revenue YoY | 3.9% | 28.5% |
| Net Profit YoY | 217.0% | 6.1% |
| EPS (diluted) | $0.19 | $0.31 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $722.5M | $1.2B | ||
| Q4 25 | $814.3M | $1.2B | ||
| Q3 25 | $784.5M | $1.3B | ||
| Q2 25 | $724.5M | — | ||
| Q1 25 | $695.4M | $1.0B | ||
| Q4 24 | $730.5M | $986.0M | ||
| Q3 24 | $702.5M | $974.0M | ||
| Q2 24 | $701.8M | $965.0M |
| Q1 26 | $78.0M | $192.0M | ||
| Q4 25 | $35.1M | $134.0M | ||
| Q3 25 | $2.4M | $135.0M | ||
| Q2 25 | $22.4M | — | ||
| Q1 25 | $12.2M | $142.0M | ||
| Q4 24 | $-31.1M | $159.0M | ||
| Q3 24 | $-156.0K | $161.0M | ||
| Q2 24 | $6.0M | $181.0M |
| Q1 26 | 44.3% | 78.4% | ||
| Q4 25 | 36.5% | 78.2% | ||
| Q3 25 | 34.9% | 78.8% | ||
| Q2 25 | 39.5% | — | ||
| Q1 25 | 36.8% | 80.3% | ||
| Q4 24 | 36.0% | 80.4% | ||
| Q3 24 | 38.4% | 80.1% | ||
| Q2 24 | 35.6% | 80.3% |
| Q1 26 | — | 34.9% | ||
| Q4 25 | 13.8% | 35.9% | ||
| Q3 25 | 9.0% | 35.5% | ||
| Q2 25 | 15.4% | — | ||
| Q1 25 | 14.4% | 41.3% | ||
| Q4 24 | 10.4% | 37.9% | ||
| Q3 24 | 12.6% | 41.3% | ||
| Q2 24 | 13.6% | 43.2% |
| Q1 26 | 10.8% | 15.5% | ||
| Q4 25 | 4.3% | 11.0% | ||
| Q3 25 | 0.3% | 10.7% | ||
| Q2 25 | 3.1% | — | ||
| Q1 25 | 1.8% | 14.1% | ||
| Q4 24 | -4.3% | 16.1% | ||
| Q3 24 | -0.0% | 16.5% | ||
| Q2 24 | 0.9% | 18.8% |
| Q1 26 | $0.19 | $0.31 | ||
| Q4 25 | $0.10 | $0.21 | ||
| Q3 25 | $0.01 | $0.22 | ||
| Q2 25 | $0.07 | — | ||
| Q1 25 | $0.04 | $0.22 | ||
| Q4 24 | $-0.10 | $0.26 | ||
| Q3 24 | $0.00 | $0.26 | ||
| Q2 24 | $0.02 | $0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | — |
| Total DebtLower is stronger | — | $8.4B |
| Stockholders' EquityBook value | — | $2.3B |
| Total Assets | — | $15.8B |
| Debt / EquityLower = less leverage | — | 3.61× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $282.0M | — | ||
| Q3 25 | $201.2M | — | ||
| Q2 25 | $71.5M | — | ||
| Q1 25 | $59.2M | $1.0B | ||
| Q4 24 | $110.6M | $883.0M | ||
| Q3 24 | $74.0M | $737.0M | ||
| Q2 24 | $43.8M | $644.0M |
| Q1 26 | — | $8.4B | ||
| Q4 25 | $2.6B | $8.7B | ||
| Q3 25 | $2.6B | $8.9B | ||
| Q2 25 | $2.2B | — | ||
| Q1 25 | $2.2B | $8.3B | ||
| Q4 24 | $2.4B | $8.5B | ||
| Q3 24 | $2.4B | $8.5B | ||
| Q2 24 | $2.4B | $8.5B |
| Q1 26 | — | $2.3B | ||
| Q4 25 | $-70.8M | $2.5B | ||
| Q3 25 | $-109.5M | $2.4B | ||
| Q2 25 | $-112.1M | — | ||
| Q1 25 | $-131.7M | $2.3B | ||
| Q4 24 | $-109.3M | $2.2B | ||
| Q3 24 | $-93.4M | $2.1B | ||
| Q2 24 | $-57.5M | $2.0B |
| Q1 26 | — | $15.8B | ||
| Q4 25 | $3.7B | $16.1B | ||
| Q3 25 | $3.6B | $16.4B | ||
| Q2 25 | $3.4B | — | ||
| Q1 25 | $3.4B | $15.5B | ||
| Q4 24 | $3.5B | $15.4B | ||
| Q3 24 | $3.5B | $15.5B | ||
| Q2 24 | $3.5B | $15.4B |
| Q1 26 | — | 3.61× | ||
| Q4 25 | — | 3.54× | ||
| Q3 25 | — | 3.75× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 3.64× | ||
| Q4 24 | — | 3.94× | ||
| Q3 24 | — | 4.06× | ||
| Q2 24 | — | 4.33× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMRX
| Affordable Medicines net | $423.0M | 59% |
| AvKARE net | $166.0M | 23% |
| Specialty net | $133.0M | 18% |
GEN
| Cyber Safety Platform | $819.0M | 66% |
| Trust Based Solutions | $421.0M | 34% |
| Net Interest Income On Notes Receivable | $4.0M | 0% |
